Skip to main content

Table 3 Correlation between statin therapy and the prevalence of CSVD at baseline in the cohort study

From: Assessing the effectiveness of statin therapy for alleviating cerebral small vessel disease progression in people ≥75 years of age

  Beta Wald OR (95% CI) P value
Prevalence of Fazekas scale ≥2
 Model 1 −0.783 4.833 0.457 (0.227, 0.919) 0.028
 Model 2 −0.734 4.478 0.480 (0.243, 0.947) 0.034
 Model 3 −0.734 4.501 0.480 (0.244, 0.946) 0.034
Prevalence of lacunes
 Model 1 −0.917 5.533 0.400 (0.186, 0.858) 0.019
 Model 2 −0.842 4.820 0.431 (0.203, 0.914) 0.028
 Model 3 −0.806 4.449 0.447 (0.211, 0.945) 0.035
Prevalence ofVirchow-Robin spaces
 Model 1 −0.614 4.305 0.541 (0.296, 0.990) 0.038
 Model 2 −0.592 3.916 0.553 (0.307, 0.994) 0.045
 Model 3 −0.578 3.581 0.561 (0.315, 0.999) 0.048
Prevalence of microbleeds
 Model 1 0.066 0.037 1.069 (0.544, 2.100) 0.847
 Model 2 0.059 0.027 1.060 (0.528, 2.218) 0.869
 Model 3 0.017 0.002 1.017 (0.516, 2.007) 0.960
  1. Model 1: Adjusted for age and sex
  2. Model 2: model 1 + smoking, alcohol intake, history of hypertension, diabetes, and dyslipidemia; medication for hypertension, diabetes, and platelet aggregation
  3. Model 3: model 2 + body mass index, blood pressure, fasting blood glucose, and blood lipids